版本:
中国

BRIEF-Catalyst Biosciences announces emergence from key patent opposition period supporting marzeptacog alfa

March 30 Catalyst Biosciences Inc

* Catalyst Biosciences announces emergence from key patent opposition period supporting marzeptacog alfa (activated), catalyst's lead clinical program

* Catalyst Biosciences - Inc Research selected as CRO for Phase 2/3 efficacy clinical trial of Factor VIIA, marzeptacog alfa (activated); trial to commence in Q4 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐